100
Participants
Start Date
June 21, 2023
Primary Completion Date
February 29, 2028
Study Completion Date
February 28, 2030
Epcoritamab
T-cell bispecific antibody, via subcutaneous injection
Rituximab
Chimeric anti-CD20 monoclonal antibody, via IV infusion
RECRUITING
University of Rochester Medical Center, Rochester
RECRUITING
The Ohio State University Wexner Medical Center, Columbus
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
Dana-Farber Cancer Institute, Boston